Part
01
of one
Part
01
Please provide me with global revenue for the following brands: AcneFree, PanOxyl, and Murad.
Hello! Thanks for asking Wonder for the global revenue for AcneFree, PanOxyl, and Murad. In short, AcneFree has global revenues of approximately $16.85 million. PanOxyl has estimated revenues of $26.31 million. Murad had revenues of $115 million in 2014 and may have revenues of $116,152,875, as of 2016. Below and in the attached spreadsheet, please find the results of my research.
METHODOLOGY
I began by researching each brand to determine if it was privately held or a brand owned by a larger company. I determined that all three brands are owned by public companies, though these companies do not segment their financial data to the level of granularity to reveal the revenue associated with specific brands. So, then I searched for secondary sources that might offer revenue data, as well as third-party sources, such as Owler and Hoovers, that offer revenue estimations. I used all available data to triangulate the revenue for each brand, which I have explained in greater detail below.
ACNEFREE
AcneFree was owned by the public company Valeant until 2017. Valeant sold its AcneFree, CeraVe, and Ambi skin care lines to L'Oreal in early 2017. At the time, revenue for the three brands totaled $168 million, and CeraVe made up $135 million of that figure. So, that would leave AcneFree and Ambi to split the $33 million. If we speculate that the split is actually even, then each brand would have revenues of $16.5 million. A 2015 Statista report states that AcneFree had revenues of $17.2 million. So, if we average these two revenue figures, we can estimate that AcneFree has revenues of approximately $16.85 million.
PANOXYL
PanOxyl is a consumer acne medication manufactured by Stiefel, a GSK company. It falls into GSK's skin health category, which is part of its consumer healthcare segment. The skin health category showed revenues of £570 million ($736.55 million US).
PanOxyl is one of 28 products in the GSK skin health business category, according to a company report by ICICI Securities Ltd. I was unable to find any information on PanOxyl's contribution to overall revenue. So if we assume, conservatively, that each of those 28 products carries an equal share of the segment's revenue, then PanOxyl would have estimated revenues of $26.31 million ($736.55 million / 28).
Unfortunately, after extensive searching, I found no other data specific to PanOxyl. Most of GSK's annual report data only segments to the consumer healthcare segment. The skin health category was only called out specifically in the aforementioned report.
MURAD
Murad was acquired by Unilever in September 2015. As of 2014, Murad had revenues of $115 million, according to a report by Fung Business Intelligence Centre. A Forbes article backs up this figure. The only other data that specifically mentioned Murad in relation to revenue data was in a report by Nasdaq regarding Unilever's recent acquisitions in its personal care segment. That report notes that cumulative pre-acquisition revenues for six companies, including Murad, were $780 million. The report mentions that Dollar Shave Club makes up $152 million of that figure. I also checked Unilever's most recent annual report and earnings call transcript, but there was no mention of Murad's contribution to overall revenue figures.
In 2016, Unilever's personal care segment, which includes Murad, experienced 0.5% growth, following 2015 growth of 13.2% with the acquisition of Murad and other brands. If we apply the 0.5% growth rate to the last known revenue for Murad, it would suggest their revenue may be at least $116,152,875 (115 million x (1.005)^2), as of 2016.
SUMMARY
To sum up, AcneFree has revenues of approximately $16.85 million. PanOxyl has estimated revenues of $26.31 million. Murad had revenues of $115 million in 2014 and may have revenues of $116,152,875, as of 2016. The requested data is outlined in the attached spreadsheet, as requested.
Thanks for using Wonder for your research needs! Please let us know if we can be of further assistance.